Neoadjuvant Nivolumab Plus Ipilimumab Versus Adjuvant Nivolumab in Macroscopic, Resectable Stage III Melanoma: The Phase 3 NADINA Trial

May 12, 2026

Upload by Levi

The phase 3 NADINA trial evaluates neoadjuvant immunotherapy with ipilimumab plus nivolumab, followed by response-driven adjuvant therapy, versus standard lymph node dissection followed by adjuvant nivolumab in macroscopic, resectable stage III melanoma. Patients naive to ICI and BRAFi/MEKi were randomized to receive two cycles of neoadjuvant therapy plus surgery, or standard treatment with adjuvant nivolumab. The primary endpoint, event-free survival from randomization, was assessed using Cox regression with an interim Haybittle-Peto rule. Neoadjuvant treatment significantly improved 12-month EFS (83.7% vs 57.2%; HR 0.32) with manageable toxicity profiles.

Share with

May 12, 2026